PECU: A multicenter study on pediatric patients with cold-induced urticaria
Betul Gemici Karaaslan, Zeynep Meric, Sezin Aydemir, Haluk Cokugras, Esra Yucel, Ayca Kiykim, Ozgen Soyoz, Figen Celebi Celik, Ozlem Sancakli, Demet Can ...
article (Uluslararası, Hakemli) | Yazar(lar): Betul Gemici Karaaslan, Zeynep Meric, Sezin Aydemir, Haluk Cokugras, Esra Yucel, Ayca Kiykim, Ozgen Soyoz, Figen Celebi Celik, Ozlem Sancakli, Demet Can ... | Yıl: 2026 | Dergi/Kurum: PEDIATRIC ALLERGY AND IMMUNOLOGY | İndeks: WOS.SCI | DOI: 10.1111/pai.70379 | Anahtar Keli
Background: Cold-induced urticaria (ColdU) is a rare chronic inducible urticaria that can cause systemic reactions, including cold-induced anaphylaxis (ColdA), but pediatric data are limited. The aim of this study was to evaluate the clinical characteristics, comorbidities, management approaches, risk of anaphylaxis, and long-term course of ColdU in a pediatric cohort, and to identify risk factors for ColdA, determinants of disease resolution, and predictors of persistence into adulthood. Methods: This retrospective multicenter study included 203 pediatric patients with ColdU across 30 centers in T & uuml;rkiye. Clinical characteristics and management of patients were analyzed. Logistic regression was used to identify factors associated with ColdA and disease resolution. Results: The median age at diagnosis was 14.3 years, and the median age at onset was 10 years; 56.1% of patients were female. ColdA occurred in 17.2%, with increased risk associated with male sex, autoimmune comorbidities, older age, and triggering by cold food/beverage ingestion. Most patients (82.2%) received second-generation H1-antihistamines; omalizumab achieved >90% symptom control in 12 refractory cases. Over a median 3.5-year follow-up, 30.5% achieved disease resolution (median duration: 18 months). The history of anaphylaxis and comorbid atopy significantly reduced the likelihood of remission. Some patients showed adult persistence, without clear predictors. Discussion: ColdA may occur even without classic high-risk features; pediatric ColdU management should be guided by individualized risk assessment, prioritizing clinical risk factors-such as older age, high-risk cold triggers, angioedema, and autoimmune comorbidities-over isolated diagnostic parameters. In refractory cases, omalizumab is an effective and well-tolerated option. Prior anaphylaxis and comorbid allergic disease predicted poorer remission.